Impaired Oxygen on-Kinetics in Persons with Human Immunodeficiency Virus Are Not Due to Highly Active Antiretroviral Therapy

Archives of Physical Medicine and Rehabilitation

Volumn 84, Issue 12, 2003, Pages 1831-1838

  Cade, W Todd ^a,c   Fantry, Lori E ^a   Nabar, Sharmila R ^a   Shaw, Donald K ^b   Keyser, Randall E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b TEXAS STATE UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Exercise; HIV; Kinetics; Oxygen; Rehabilitation

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AEROBIC METABOLISM; ARTICLE; BREATHING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXERCISE TEST; EXHAUSTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUSCLE METABOLISM; OXYGEN CONSUMPTION; OXYGEN ON KINETICS; OXYGENATION; OXYGENATION IMPAIRMENT; RESPONSE TIME; TREADMILL EXERCISE;

EID: 0345097603     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2003.03.004     Document Type: Article

References (71)

1. Cade WT, Fantry LE, Nabar SR, Keyser RE. Decreased peak arteriovenous oxygen difference during treadmill exercise testing in individuals infected with human immunodeficiency virus. Arch Phys Med Rehabil 2003;84:1595-603.
2. Grau JM, Masanes F, Pedrol E, Casademont J, Fernandez-Sola J, Urbano-Marquez A. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Ann Neurol 1993;34:206-11.
3. Morgello S, Wolfe D, Godfrey E, Feinstein R, Tagliati M, Simpson DM. Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy. Acta Neuropathol 1995;90:366-74.
4. Gherardi RK. Skeletal muscle involvement in HIV-infected patients. Neuropathol Appl Neurobiol 1994;20:232-7.
5. Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-1 I and HTLV-1 I infected patients. Brain 1996;119(Pt 6):1887-93.
6. Lane RJ, McLean KA, Moss J, Woodrow DF. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions. Neuropathol Appl Neurobiol 1993;19:406-13.
7. Simpson DM, Citak KA, Godfrey E, Godbold J, Wolfe DE. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology 1993;43:971-6.
8. Dalakas MC, Pezeshkpour GH, Gravell M, Sever JL. Polymyositis associated with AIDS retrovirus. JAMA 1986;256:2381-3.
9. Chad DA, Smith TW, Blumenfeld A, Fairchild PG, DeGirolami U. Human immunodeficiency virus (HIV)-associated myopathy: immunocytochemical identification of an HIV antigen (gp 41) in muscle macrophages. Ann Neurol 1990;28:579-82.
10. Chariot P, Benbrik E, Schaeffer A, Gherardi R. Tubular aggregates and partial cytochrome c oxidase deficiency in skeletal muscle of patients with AIDS treated with zidovudine. Acta Neuropathol 1993;85:431-6.
11. Chariot P, Monnet I, Gherardi R. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy. Ann Neurol 1993;34:561-5.
12. Chariot P, Monnet I, Mouchet M, et al. Determination of the blood lactate: pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum 1994;37:583-6.
13. Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997;149:19-25.
14. McCurdy DT 3rd, Kennedy JM. AZT decreases rat myocardial cytochrome oxidase activity and increases beta-myosin heavy chain content. J Mol Cell Cardiol 1998;30:1979-89.
15. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708.
16. Modica-Napolitano JS. AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem Biophys Res Commun 1993;194:170-7.
17. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-10.
18. Lewis W, Gonzalez B, Chomyn A, Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 1992;89:1354-60.
19. Szabados E, Fischer GM, Toth K, et al. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic Biol Med 1999;26:309-17.
20. Gonzalez Cid M, Larripa I. Genotoxic activity of azidothymidine (AZT) in in vitro systems. Mutat Res 1994;321:113-8.
21. de la Asuncion JG, del Olmo MI, Sastre J, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 1998;102:4-9.
22. 2 uptake kinetics during heavy exercise. Med Sci Sports Exerc 1994;26:1319-26.
23. Xu F, Rhodes EC. Oxygen uptake kinetics during exercise. Sports Med 1999;27:313-27.
24. Weiler-Ravell D, Cooper DM, Whipp BJ, Wasserman K. Control of breathing at the start of exercise as influenced by posture. J Appl Physiol 1983;55:1460-6.
25. Springer C, Barstow TJ, Wasserman K, Cooper DM. Oxygen uptake and heart rate responses during hypoxic exercise in children and adults. Med Sci Sports Exerc 1991;23:71-9.
26. 2 uptake and heart rate as affected by exercise work rate. J Appl Physiol 1989;67:2535-41.
27. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Centers for Disease Control and Prevention. MMWR Recomm Rep 1999;48(RR13):1-27, 29-31.
28. Center for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
29. Masanes F, Barrientos A, Cebrian M, et al. Clinical, histological and molecular reversibility of zidovudine myopathy. J Neurol Sci 1998;159:226-8.
30. Jones NL, Campbell EJ, McHardy GJ, Higgs BE, Clode M. The estimation of carbon dioxide pressure of mixed venous blood during exercise. Clin Sci 1967;32:311-27.
31. 2 rise during rebreathing. J Appl Physiol 1958;13:159-64.
32. Jones NL. Clinical exercise testing. 4th ed. Philadelphia: WB Saunders; 1997.
33. Whipp BJ. Rate constant for the kinetics of oxygen uptake during light exercise. J Appl Physiol 1971;30:261-3.
34. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
35. Pina CR. Lead systems: sensitivity and specificity. Cardiol Clin 1984;2:329-35.
36. 2 tensions by rebreathing. J Appl Physiol 1955;9:25-9.
37. 2 for determination of cardiac output in children. Chest 1997;111:474-80.
38. American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription. 6th ed. Baltimore: Lippincott, Williams & Wilkins; 2000.
39. 2 kinetics during ramp exercise criterion for cardiopulmonary exercise capacity in chronic heart failure. Med Sci Sports Exerc 1998;30:643-8.
40. 2 unloading in muscle delays oxygen uptake response to exercise onset in humans. Am J Physiol 1999;277(5 Pt 2):R1274-81.
41. 2 kinetics reveal a central limitation at the onset of subthreshold exercise in heart transplant recipients. J Appl Physiol 2000;88:1228-38.
42. Sietsema KE, Cooper DM, Perloff JK, et al. Dynamics of oxygen uptake during exercise in adults with cyanotic congenital heart disease. Circulation 1986;73:1137-44.
43. 2 uptake kinetics in response to exercise. A measure of tissue anaerobiosis in heart failure. Chest 1993;103:735-41.
44. Grassi B, Marconi C, Meyer M, Rieu M, Cerretelli P. Gas exchange and cardiovascular kinetics with different exercise protocols in heart transplant recipients. J Appl Physiol 1997;82:1952-62.
45. Bauer TA, Regensteiner JG, Brass EP, Hiatt WR. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. J Appl Physiol 1999;87:809-16.
46. Lok NS, Lau CP. Oxygen uptake kinetics and cardiopulmonary performance in lone atrial fibrillation and the effects of sotalol. Chest 1997;111:934-40.
47. Rocca HP, Weilenmann D, Follath F, et al. Oxygen uptake kinetics during low level exercise in patients with heart failure: relation to neurohormones, peak oxygen consumption, and clinical findings. Heart 1999;81:121-7.
48. Brunner-La Rocca HP, Weilenmann D, Schalcher C, et al. Prognostic significance of oxygen uptake kinetics during low level exercise in patients with heart failure. Am J Cardiol 1999;84:741-4, A9.
49. Robergs RA, Roberts SO. Exercise physiology: exercise, performance and clinical application. St. Louis: Mosby-Year Book; 1997.
50. 2 deficit in heavy exercise. J Appl Physiol 2000;88:1407-12.
51. Cabello A, Martinez-Martin P, Gutierrez-Rivas E, Madero S. Myopathy with nemaline structures associated with HIV infection. J Neurol 1990;237:64-5.
52. Panegyres PK, Papadimitriou JM, Hollingsworth PN, Armstrong JA, Kakulas BA. Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment. J Neurol Neurosurg Psychiatry 1990;53:649-55.
53. Feinberg DM, Spiro AJ, Weidenheim KM. Distinct light microscopic changes in human immunodeficiency virus-associated nemaline myopathy. Neurology 1998:50:529-31.
54. Dhawan S, Toro LA, Jones BE, Meltzer MS. Interactions between HIV-infected monocytes and the extracellular matrix: HIV-infected monocytes secrete neutral metalloproteases that degrade basement membrane protein matrices. J Leukoc Biol 1992;52:244-8.
55. Goerdt S, Sorg C. Endothelial heterogeneity and the acquired immunodeficiency syndrome: a paradigm for the pathogenesis of vascular disorders. Clin Investig 1992;70:89-98.
56. 2 kinetics in old and young individuals. J Appl Physiol 1997;82:63-9.
57. Linnarsson D. Dynamics of pulmonary gas exchange and heart rate changes at start and end of exercise. Acta Physiol Scand Suppl 1974;415:1-68.
58. Whipp BJ. Dynamics of pulmonary gas exchange. Circulation 1987;76(6 Pt 2):VI18-28.
59. Feroldi P, Belleri M, Ferretti G, Veicsteinas A. Heart rate overshoot at the beginning of muscle exercise. Eur J Appl Physiol Occup Physiol 1992;65:8-12.
60. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000;160:602-8.
61. Kaul S, Fishbein MC, Siegel RJ. Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update. Am Heart J 1991;122:535-44.
62. Yunis NA, Stone VE. Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:145-54.
63. Milei J, Grana D, Fernandez Alonso G, Matturri L. The Committee for the Study of Cardiac Involvement in AIDS. Cardiac involvement in acquired immunodeficiency syndrome - a review to push action. Clin Cardiol 1998;21:465-72.
64. Currie PF, Goldman JH, Caforio AL, et al. Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998;79:599-604.
65. Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol 1990;66:203-6.
66. Calabrese LH, Proffitt MR, Yen-Lieberman B, Hobbs RE, Ratliff NB. Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Ann Intern Med 1987;107:691-2.
67. Johnson JE, Anders GT, Blanton HM, et al. Exercise dysfunction in patients seropositive for the human immunodeficiency virus. Am Rev Respir Dis 1990;141:618-22.
68. Pothoff G, Wassermann K, Ostmann H. Impairment of exercise capacity in various groups of HIV-infected patients. Respiration 1994;61:80-5.
69. Perna FM, LaPerriere A, Klimas N, et al. Cardiopulmonary and CD4 cell changes in response to exercise training in early symptomatic HIV infection. Med Sci Sports Exerc 1999;31:973-9.
70. Keyser RE, Peralta L, Cade WT, Miller S, Anixt J. Functional aerobic impairment in adolescents seropositive for HIV: a quasiexperimental analysis. Arch Phys Med Rehabil 2000;81:1479-84.
71. 2 in individuals with HIV taking and not taking HAART. Med Sci Sport Exerc 2003;35:1108-17.